Treatment of Staphylococcal Device Infections: Synergistic Daptomycin With Ceftaroline Versus Rifampin-Adjunct Therapy | Zendy

Amy Chang | Zendy; Reese A. Cosimi | Zendy; Markian R. Bochan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Staphylococcal Device Infections: Synergistic Daptomycin With Ceftaroline Versus Rifampin-Adjunct Therapy

Author(s) -

Amy Chang,

Reese A. Cosimi,

Markian R. Bochan

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa072

Subject(s) - daptomycin , medicine , retrospective cohort study , antibiotics , salvage therapy , adjunct , methicillin resistant staphylococcus aureus , observational study , intensive care medicine , staphylococcus aureus , vancomycin , microbiology and biotechnology , chemotherapy , bacteria , linguistics , philosophy , biology , genetics

This is a single-center retrospective observational cohort study comparing daptomycin/ceftaroline combination therapy with rifampin-adjunct therapy for the treatment of staphylococcal device infections. The results of this study support use of the daptomycin/ceftaroline as an alternative or salvage option to standard of care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research